Terumo BCT, KBIOHealth to Enhance Gene Therapy Workforce in South Korea

Terumo Blood and Cell Technologies (Terumo BCT) has signed a memorandum of understanding (MOU) with the Osong Medical Innovation Foundation (KBIOHealth) to jointly develop workforce training for cell and gene therapy (CGT) manufacturing. The partnership aims to create training programs focused on mesenchymal stem cell (MSC) and chimeric antigen (CAR) T-cell therapies, utilizing Terumo BCT’s…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here